Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013 - New Report Available
Global Markets Direct's, 'Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL). Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, Half Year is built using data and information sourced...
View full press release